Vanda Pharmaceuticals (VNDA) Exchange Rate Effect (2017 - 2026)
Vanda Pharmaceuticals (VNDA) posted Exchange Rate Effect of -$57000.0 for Q1 2026, down 385.0% sequentially from $20000.0 in Q4 2025, and down 216.33% YoY from $49000.0 in Q1 2025.
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Exchange Rate Effect for 10 years, with the latest figure at -$57000.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 216.33% year-over-year to -$57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$83000.0 (up 17.0% YoY) and the FY2025 annual result came in at $23000.0, up 114.11% from the prior year.
- Exchange Rate Effect eased to -$57000.0 in Q1 2026 per VNDA's latest filing, from $20000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $183000.0 in Q4 2022 and troughed at -$202000.0 in Q4 2024.
- A 5-year average of $6764.7 and a median of $20000.0 in 2025 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 993.33% in 2025, down 364.71% in 2025.
- Over 5 years, Exchange Rate Effect stood at $183000.0 in 2022, then fell by 18.03% to $150000.0 in 2023, then plunged by 234.67% to -$202000.0 in 2024, then soared by 109.9% to $20000.0 in 2025, then tumbled by 385.0% to -$57000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$57000.0, $20000.0, and -$180000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -36,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36,000.00 |
| Mar 31, 2026 | -57,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | -180,000.00 |
| Jun 30, 2025 | 134,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | -202,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Sep 30, 2023 | -122,000.00 |
| Jun 30, 2023 | -26,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Sep 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 79,000.00 |
| Mar 31, 2022 | -57,000.00 |
| Dec 31, 2021 | -101,000.00 |
| Sep 30, 2021 | 39,000.00 |